Rinsulin NPH, 100 me/ml 3 ml cartridges 5 pcs

RINSULIN NPH is a preparation of genetically engineered human insulin. It lowers blood glucose levels, increases its uptake by tissues, increases lipogenesis, glycogenogenesis, protein synthesis, reduces the rate of glucose production by liver.

Indications

Type 1 diabetes mellitus (insulin-dependent);

Composition

How to take, the dosage

Rinsulin® NPC is contraindicated by intravenous administration.

Interaction

Hypoglycemic effect of Rinsulin NIH is enhanced by MAO inhibitors, non-selective beta-adrenoblockers, sulfonamides, anabolic steroids, tetracyclines, clofibrate, cyclophosphamide, phenfluramine, drugs containing ethanol.

Special Instructions

Patients receiving more than 100 units of RINSULIN NPC per day should be hospitalized during drug switching. Transition from one type of insulin to another should be performed under control of blood glucose levels. In connection with the initial prescription of insulin, change of its type or in the presence of significant physical or mental stress, it is possible to reduce the ability to drive a car or operate various mechanisms, as well as engage in other potentially dangerous activities that require increased attention and speed of mental and motor reactions.

Contraindications

Hypoglycemia, hypersensitivity to human insulin preparations.

Side effects

Conditioned by the effect on carbohydrate metabolism: hypoglycemic states (pale skin, increased sweating, palpitations, tremors).

Overdose

An overdose of the drug may lead to a hypoglycemic state.